Literature DB >> 17852877

Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease.

Martina Fabris1, Daniela Visentini, Valli De Re, Alessia Picierno, Roberto Maieron, Renato Cannizzaro, Danilo Villalta, Francesco Curcio, Salvatore De Vita, Elio Tonutti.   

Abstract

OBJECTIVE: The B cell-activating factor of the tumour necrosis factor (TNF) family (BAFF) was recently described as a critical survival factor for B cells, and its expression is increased in several autoimmune diseases. Abnormal production of BAFF disturbs immune tolerance allowing the survival of autoreactive B cells and participates in the progression of B-cell lymphomas. Coeliac disease (CD) is a common autoimmune disorder induced by gluten intake in genetically predisposed individuals, associated with autoantibody production and with an increased risk of lymphoma at follow-up. The purpose of this study was to investigate the possible implications of BAFF in CD.
MATERIAL AND METHODS: Seventy-three patients with small-bowel biopsies and laboratory-proven diagnosis of CD were included in the study. All serum samples were analysed before the start of a gluten-free diet (GFD). In 12 cases, one or more samples were analysed during follow-up of the GFD. Seventy-seven blood donors were taken as controls. Serum BAFF levels and anti-transglutaminase (a-tTG) antibodies were assessed by ELISA and endomysial antibodies by indirect immunofluorescence.
RESULTS: Serum BAFF levels appeared to be significantly more elevated in CD patients than in controls (p<0.0001) and, compared with other autoimmune diseases where BAFF is increased, a much larger percentage (80.8%) of CD patients presented BAFF levels above the normal range. In addition, serum BAFF levels were found to correlate with a-tTG antibody levels (p =0.0007) and there was a significant reduction of BAFF after introduction of a GFD.
CONCLUSIONS: BAFF may represent a possible pathogenic factor in CD. Its implications for the diagnosis, prognosis and treatment of CD should also be assessed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17852877     DOI: 10.1080/00365520701452225

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

Review 1.  Cutting-edge issues in celiac disease and in gluten intolerance.

Authors:  N Bizzaro; R Tozzoli; D Villalta; M Fabris; E Tonutti
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

Review 2.  The Phenotypic Difference of IgA Nephropathy and its Race/Gender-dependent Molecular Mechanisms.

Authors:  Yusuke Suzuki; Renato C Monteiro; Rosanna Coppo; Hitoshi Suzuki
Journal:  Kidney360       Date:  2021-05-28

Review 3.  Manipulating B cell homeostasis: a key component in the advancement of targeted strategies.

Authors:  Laura S Treml; William J Quinn; John F Treml; Jean L Scholz; Michael P Cancro
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

4.  Potential blood-based markers of celiac disease.

Authors:  Hanna Bragde; Ulf Jansson; Mats Fredrikson; Ewa Grodzinsky; Jan Söderman
Journal:  BMC Gastroenterol       Date:  2014-10-09       Impact factor: 3.067

5.  B cell activating factor of the tumor necrosis factor family (BAFF) behaves as an acute phase reactant in acute pancreatitis.

Authors:  Georg Pongratz; Hannah Hochrinner; Rainer H Straub; Stefanie Lang; Tanja Brünnler
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

6.  Serum cytokine pattern in young children with screening detected coeliac disease.

Authors:  S Björck; S R Lindehammer; M Fex; D Agardh
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.